CRP and neoplasm: Results: The calculated risk estimation of a reduced follow-up time was 2.25 timed higher in the patients with a CRP level >0.5 mg/dL (HR 2.25 and 95% CI 1.13–4.45) and 3 times higher in patients with a tumor size > pT2 (HR 3 and 95% CI 1.59–5.92).